- Nachrichtendetail
-
21.02.2024 13:12:52 - dpa-AFX: *REGENERON PHARMA: FDA ACCEPTS FOR PRIORITY REVIEW BLA FOR LINVOSELTAMAB FOR TREATMENT OF R/R MULTIPLE MYELOMA
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Regeneron Pharmaceuticals | 881535 | NASDAQ | 989,480 | 03.06.24 22:00:10 | +9,320 | +0,95% | 980,000 | 998,860 | 980,160 | 980,160 |
